9-[(5.6.7,8-tetrahydronaphthalen-2-yloxy)methyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide | 1358752-46-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 9-[(5.6.7,8-tetrahydronaphthalen-2-yloxy)methyl]-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide
• 英文别名: 9-(5,6,7,8-Tetrahydronaphthalen-2-yloxymethyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide
• CAS: 1358752-46-1
• 化学式: C₁₈H₂₄N₂O₃S
• 分子量: 348.466
• InChiKey: CKMQHGOOVXOSSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：KORI Masakuni

  公开号：US20120077799A1

  公开（公告）日：2012-03-29

  Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

  提供的化合物由公式(I)表示，其中每个符号如规范中所定义，或其盐，具有AMPA（α-氨基-3-羟基-5-甲基-4-异唑烷丙酸）受体增强作用。本发明的化合物可用作预防或治疗抑郁症、精神分裂症、阿尔茨海默病或注意力缺陷多动障碍（ADHD）等疾病的药物。
• Heterocyclic compound and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10654874B2

  公开（公告）日：2020-05-19

  Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

  本文提供了一种由式 (I) 表示的化合物： 其中各符号如说明书中所定义，或其盐，具有 AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体增效作用。本发明化合物可用作抑郁症、精神分裂症、阿尔茨海默病或注意力缺陷多动障碍（ADHD）等疾病的预防或治疗药物。
• HETEROCYCLIC COMPOUND AND USE THEREOF AS AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2603513B1

  公开（公告）日：2020-03-11
• US8575154B2
  申请人：——

  公开号：US8575154B2

  公开（公告）日：2013-11-05
• US8778934B2
  申请人：——

  公开号：US8778934B2

  公开（公告）日：2014-07-15